Lenvatinib Plus I-125 Seed Brachytherapy vs. Lenvatinib for TACE-refractory HCC

Condition:   Hepatocellular Carcinoma Non-resectable Interventions:   Procedure: Lenvatinib Plus I-125 Seed Brachytherapy;   Drug: Lenvatinib Sponsor:   Second Affiliated Hospital of Guangzhou Medical University Recruiting
Source: ClinicalTrials.gov - Category: Research Source Type: clinical trials